Blocking TIM3 receptor on cDC1 in breast cancer has shown an improved anti‐tumour response after chemotherapy by promoting intra‐tumour CD8+ T response mediated by CXCL9 expression. This evidence concerns the gene CXCL9 and breast cancer.